WO2000001813A3 - Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene - Google Patents
Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene Download PDFInfo
- Publication number
- WO2000001813A3 WO2000001813A3 PCT/CA1999/000604 CA9900604W WO0001813A3 WO 2000001813 A3 WO2000001813 A3 WO 2000001813A3 CA 9900604 W CA9900604 W CA 9900604W WO 0001813 A3 WO0001813 A3 WO 0001813A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- androgen
- independent activation
- androgen receptor
- receptor
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002302169A CA2302169A1 (fr) | 1998-06-30 | 1999-06-30 | Inhibiteurs du phenomene d'activation ne dependant pas de l'androgene et ayant un effet sur le recepteur de l'androgene |
AU44943/99A AU4494399A (en) | 1998-06-30 | 1999-06-30 | Inhibitors of androgen-independent activation of androgen receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9187198P | 1998-06-30 | 1998-06-30 | |
US60/091,871 | 1998-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001813A2 WO2000001813A2 (fr) | 2000-01-13 |
WO2000001813A3 true WO2000001813A3 (fr) | 2000-04-13 |
Family
ID=22230037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000604 WO2000001813A2 (fr) | 1998-06-30 | 1999-06-30 | Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4494399A (fr) |
CA (1) | CA2302169A1 (fr) |
WO (1) | WO2000001813A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003018987A (ja) * | 2001-06-25 | 2003-01-21 | Okazaki National Research Institutes | 遺伝子導入細胞及びそれを用いた撹乱物質の検出法 |
US20100189776A1 (en) * | 2007-03-16 | 2010-07-29 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
US20100291086A1 (en) * | 2007-09-11 | 2010-11-18 | Christopher Hovens | Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers |
FR2938334A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
BRPI0913673A2 (pt) | 2008-07-02 | 2015-10-13 | British Columbia Cancer Agency | uso de um composto, composição farmacêutica, e, método para modular a atividade do receptor de andrógeno |
CN102131775B (zh) | 2008-08-22 | 2015-12-16 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体n-末端活化的小分子抑制剂 |
EP2521707B1 (fr) | 2010-01-06 | 2017-06-14 | British Columbia Cancer Agency Branch | Dérivés du bisphénol et leur utilisation en tant que modulateurs de l'activité du récepteur des androgènes |
EP2693875A4 (fr) | 2011-04-08 | 2014-10-22 | British Columbia Cancer Agency | Composés de bisphénol et leurs procédés d'utilisation |
WO2013028572A1 (fr) | 2011-08-19 | 2013-02-28 | British Columbia Cancer Agency Branch | Composés d'éthers de bisphénol fluorés et leurs procédés d'utilisation |
GB2496135B (en) * | 2011-11-01 | 2015-03-18 | Valirx Plc | Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
GB2513615A (en) | 2013-05-01 | 2014-11-05 | Cancer Rec Tech Ltd | Medical use |
CN105358522A (zh) | 2013-05-10 | 2016-02-24 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体调节剂的酯衍生物及其使用方法 |
US9375496B2 (en) | 2013-09-09 | 2016-06-28 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
AU2015266654A1 (en) | 2014-05-30 | 2016-12-01 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
ES2907708T3 (es) | 2015-01-13 | 2022-04-26 | British Columbia Cancer Agency Branch | Compuestos heterocíclicos para obtención de imágenes y tratamiento del cáncer y métodos para su uso |
WO2016141458A1 (fr) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Dérivés d'éther de bisphénol et leurs procédés d'utilisation |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
US20190345202A1 (en) * | 2016-08-08 | 2019-11-14 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
KR20210093886A (ko) | 2018-10-18 | 2021-07-28 | 에싸 파마 아이엔씨. | 안드로겐 수용체 조절제 및 그 사용 방법 |
EP4135675A4 (fr) | 2020-04-17 | 2024-04-10 | Essa Pharma, Inc. | Formes solides d'un inhibiteur de récepteur des androgènes de domaine n-terminal et leurs utilisations |
WO2023046283A1 (fr) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Composés et leur utilisation dans une méthode de modulation de l'activité transcriptionnelle d'ar (récepteur des androgènes) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989009791A1 (fr) * | 1988-04-14 | 1989-10-19 | University Of North Carolina At Chapel Hill | Adn codant pour des proteines receptrices d'androgene |
EP0577932A2 (fr) * | 1992-05-08 | 1994-01-12 | American Cyanamid Company | Développement d'un "screening" basé en mécanisme pour identifier agonistes et antagonistes du récepteur d'androgène |
WO1997030074A1 (fr) * | 1996-02-16 | 1997-08-21 | Cytogen Corporation | Isolation et utilisation de peptides de liaison de sh3 |
-
1999
- 1999-06-30 CA CA002302169A patent/CA2302169A1/fr not_active Abandoned
- 1999-06-30 AU AU44943/99A patent/AU4494399A/en not_active Abandoned
- 1999-06-30 WO PCT/CA1999/000604 patent/WO2000001813A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989009791A1 (fr) * | 1988-04-14 | 1989-10-19 | University Of North Carolina At Chapel Hill | Adn codant pour des proteines receptrices d'androgene |
EP0577932A2 (fr) * | 1992-05-08 | 1994-01-12 | American Cyanamid Company | Développement d'un "screening" basé en mécanisme pour identifier agonistes et antagonistes du récepteur d'androgène |
WO1997030074A1 (fr) * | 1996-02-16 | 1997-08-21 | Cytogen Corporation | Isolation et utilisation de peptides de liaison de sh3 |
Non-Patent Citations (7)
Title |
---|
CHAMBERLAIN, N L ET AL.,: "Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26772 - 26778, XP002130096 * |
CULIG Z ET AL.,: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor", CANCER RESEARCH, vol. 54, 15 October 1994 (1994-10-15), pages 5474 - 5478, XP000867802 * |
DE RUITER PE ET AL.,: "Synergism between androgens and protein kinase-C on androgen regulated gene expression", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 110, 1995, pages r1 - r6, XP000874779 * |
JENSTER G ET AL.,: "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7341 - 7346, XP000867758 * |
JIA L D ET AL: "Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 9, 1996, pages 531-539, XP004070285, ISSN: 0039-128X * |
NAZARETH LV AND WEIGEL NL: "Activation of human androgen receptor through a protein kinase A signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 19900 - 19907, XP002130095 * |
SADAR MD: "Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 12 March 1999 (1999-03-12), pages 7777 - 7783, XP002130097 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000001813A2 (fr) | 2000-01-13 |
AU4494399A (en) | 2000-01-24 |
CA2302169A1 (fr) | 2000-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000001813A3 (fr) | Inhibiteurs de l'activation independante de l'androgene du recepteur d'androgene | |
WO2000040614A3 (fr) | Caracterisation d'une famille de canaux calciques | |
MY120693A (en) | Human bikunin | |
CA2184908A1 (fr) | Cathepsine derivee d'osteoclaste humain | |
WO2001036640A3 (fr) | Gene humain fgf-21 et produits d'expression genique | |
EP1194164B8 (fr) | Peptides proteiniques du prion et utilisations associees | |
EP2258383A3 (fr) | Peptides antigènes dérivés de la télomérase | |
WO2002074337A8 (fr) | Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires | |
WO2001018046A3 (fr) | Sequences de tumeurs ovariennes et procedes d'utilisation correspondants | |
ATE299510T1 (de) | Peptide als kalium kanalaktivatoren | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
WO2003016342A3 (fr) | Antigenes tumoraux pour la prevention et/ou le traitement du cancer | |
UA72875C2 (uk) | БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ | |
WO2002094859A3 (fr) | Peptides mage-a1 permettant le traitement ou la prevention du cancer | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
WO2002034915A3 (fr) | Segments preferes de la proteine neurale ntp et ses procedes d'utilisation | |
PT938329E (pt) | Composicao de tlp imunogenica | |
BR0008917A (pt) | Compostos | |
WO2000024771A3 (fr) | Acides nucleiques codant pour des proteines semblables a l'osteoprotegerine et methodes d'utilisation associees | |
HRP970693B1 (en) | Cycloalkyl inhibitors of protein farnesyltransferase | |
WO2002030977A3 (fr) | Proteine a motif egf, materiaux egfl6 et procedes | |
DE60120187D1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
AU2375895A (en) | Methods for detection and therapy of squamous cell carcinoma and bladder carcinoma, in particular for determining the pr esence and treatment of minimal residual disease, micrometas tases or dissemination of such carcinoma types | |
AU2990300A (en) | Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use | |
WO2001087934A3 (fr) | Peptides carboxy-terminaux du gene transformant de la tumeur de l'hypophyse (pttg) et leurs procedes d'utilisation visant a inhiber une proliferation et/ou une transformation cellulaires neoplasiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Kind code of ref document: A Ref document number: 2302169 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09515886 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |